-
Stephen P Adams, Nima Alaeiilkhchi, Sara Tasnim, James M WrightKey messagesPravastatin decreases low‐density lipoprotein cholesterol and the effect is dependent on the dose over the range of 5 mg to 160 mg.Pravastatin at 80 mg/day is the maximal licensed dose.From other systematic reviews we conducted, pravastatin has a similar effect on...
September 21 2023
-
Marcia Reinhart, Lorri Puil, Douglas M Salzwedel, James M WrightKey messagesThiazides and thiazide‐like drugs (diuretics) probably decrease some adverse cardiovascular events compared to beta‐blockers, calcium channel blockers, ACE inhibitors, and alpha‐blockers when used as the first‐line drug for the treatment of hypertension. Total...
July 13 2023
-
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Spring 2023) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...
May 9 2023
-
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Winter 2023) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...
December 20 2022
-
Luis Carlos Saiz, Javier Gorricho, Javier Garjón, Maria Concepción Salaya, Juan Erviti, Leire LeacheKey messagesThe evidence identified in this review does not support lower blood pressure goals over standard goals in people with high blood pressure (also known as hypertension) and heart or vascular (blood vessels and circulatory system) problems...
November 22 2022
-
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Summer 2022) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...
August 10 2022
-
Eduard Shantsila, Monika Kozieł-Siołkowska, Gregory LipReview questionWe reviewed the evidence that examined whether antiplatelet agents reduced total deaths or major thrombotic events or both in patients with elevated blood pressure (BP) when compared to placebo or other active treatment. We also assessed whether oral anticoagulants reduced total...
August 9 2022
-
A new chapter for CochraneCochrane has embarked on an important change programme to transform the way we produce the high-quality, independent and timely evidence. The new model is designed to ensure Cochrane remains viable, sustainable, and focused on the greatest global health and care challenges now and into the future. As part of the...
June 27 2022
-
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Spring 2022) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...
April 22 2022
-
Plain language summary:Review questionWe wanted to find out the effects of calcium intake on blood pressure in people with normal blood pressure. BackgroundHypertension is a serious health problem that increases the risk of heart and kidney diseases. Several studies have shown that increasing calcium intake lowers blood pressure even in...
March 1 2022
Stephen P Adams, Nima Alaeiilkhchi, Sara Tasnim, James M WrightKey messagesPravastatin decreases low‐density lipoprotein cholesterol and the effect is dependent on the dose over the range of 5 mg to 160 mg.Pravastatin at 80 mg/day is the maximal licensed dose.From other systematic reviews we conducted, pravastatin has a similar effect on...September 21 2023
Marcia Reinhart, Lorri Puil, Douglas M Salzwedel, James M WrightKey messagesThiazides and thiazide‐like drugs (diuretics) probably decrease some adverse cardiovascular events compared to beta‐blockers, calcium channel blockers, ACE inhibitors, and alpha‐blockers when used as the first‐line drug for the treatment of hypertension. Total...July 13 2023
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Spring 2023) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...May 9 2023
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Winter 2023) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...December 20 2022
Luis Carlos Saiz, Javier Gorricho, Javier Garjón, Maria Concepción Salaya, Juan Erviti, Leire LeacheKey messagesThe evidence identified in this review does not support lower blood pressure goals over standard goals in people with high blood pressure (also known as hypertension) and heart or vascular (blood vessels and circulatory system) problems...November 22 2022
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Summer 2022) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...August 10 2022
Eduard Shantsila, Monika Kozieł-Siołkowska, Gregory LipReview questionWe reviewed the evidence that examined whether antiplatelet agents reduced total deaths or major thrombotic events or both in patients with elevated blood pressure (BP) when compared to placebo or other active treatment. We also assessed whether oral anticoagulants reduced total...August 9 2022
A new chapter for CochraneCochrane has embarked on an important change programme to transform the way we produce the high-quality, independent and timely evidence. The new model is designed to ensure Cochrane remains viable, sustainable, and focused on the greatest global health and care challenges now and into the future. As part of the...June 27 2022
Cochrane Hypertension publishes a quarterly newsletter with updates on our systematic reviews, training, and other editorial team activities and news. Subscribe to the Cochrane HTN newsletter.Our latest newsletter (Spring 2022) is now availableIf you have feedback on current or past newsletters, or suggestions for future newsletter topics,...April 22 2022
Plain language summary:Review questionWe wanted to find out the effects of calcium intake on blood pressure in people with normal blood pressure. BackgroundHypertension is a serious health problem that increases the risk of heart and kidney diseases. Several studies have shown that increasing calcium intake lowers blood pressure even in...March 1 2022